Members & Technology Partners | Structural Genomics Consortium

SGC is a UK-registered charity that supports seven open science research sites worldwide.

SGC brings together a global network of organizations that support and collaborate on scientific research without retaining intellectual property rights or advanced knowledge of outputs. These include funding Members (Pfizer, Amgen, Novo Nordisk, AstraZeneca, Bristol Myers Squibb, Janssen) and Technology Partners (Nuvisan, Chemspace, Vernalis) who contribute expertise and capabilities across SGC research and affiliated initiatives.

Pfizer

Pfizer is the world's leading biopharmaceutical company. Pfizer’s mission is to discover and develop innovative medicines and other products to improve the quality of life of people and animals around the world.

Amgen

Amgen Inc. is a leading independent global biotechnology company focused on discovering, developing, and delivering innovative human therapeutics in oncology, cardiology, bone health, inflammation, and nephrology.

Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Their purpose is to drive change to defeat serious chronic diseases.

Bristol Myers Squibb (BMS)

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience.

Janssen, Pharmaceutical Companies of Johnson & Johnson

Janssen, Pharmaceutical Companies of Johnson & Johnson is a focused healthcare company, with expertise in Innovative Medicine and MedTech, bringing innovative, effective treatments in five therapeutic areas: cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience and oncology.

AstraZeneca

AstraZeneca is a science-led biopharmaceutical company pushing the boundaries of science to deliver life-changing medicines.

Chemspace

Chemspace is a leading online platform and service provider for drug discovery, specialized in virtual screening, hit identification, and compound sourcing, assisting researchers with AI-driven drug discovery, chemical modeling, and laboratory services.

Nuvisan

Nuvisan is the unique CRO/CDMO with extensive pharma experience and industry-leading scientific expertise, providing highest-quality end-to-end solutions.

Vernalis

Vernalis Research develops and applies fragment and structure-based methods to drug discovery and has generated cell-active lead compounds and development candidates against biological targets in oncology, neurodegeneration, anti-infectives, and inflammation.

Funding Acknowledgement

The Structural Genomics Consortium (SGC) is a registered charity (no: 1097737) that receives direct member funding from Amgen Inc., Janssen Pharmaceutica NV, and Bristol-Myers Squibb Company, as well as grant funding from the Innovative Health Initiative Joint Undertaking (IHI JU; LIGAND-AI, grant agreement No. 101252959), the Gates Foundation and the Michael J. Fox Foundation.

Through the IHI LIGAND-AI grant, SGC also receives financial and in-kind contributions from Pfizer Inc., AstraZeneca UK Limited, and Novo Nordisk A/S, Abcam Limited, Chemspace LLC, Enamine Germany GmbH, IBM Research Israel – Science and Technology Ltd., Nuvisan ICB GmbH, Thermo Fisher Scientific (Bremen) GmbH, The Hospital for Sick Children, and Vernalis (R&D) Limited.

SGC Policy on Overheads

SGC does not permit the use of its grant funds to pay university overheads